GENFIT S A/ADR (NASDAQ:GNFT) Cut to “Sell” at Zacks Investment Research
According to Zacks, “Genfit SA is a biopharmaceutical company. It focuses on the discovery and development of therapeutic and diagnostic solutions in metabolic and liver related diseases. The company’s lead products include Elafibranor, Nitazoxanide and TGFTX1 which are in clinical stage. Genfit SA is based in Loos, France. “
A number of other equities research analysts have also issued reports on GNFT. Stifel Nicolaus initiated coverage on shares of GENFIT S A/ADR in a report on Tuesday, June 25th. They set a hold rating on the stock. HC Wainwright reduced their target price on shares of GENFIT S A/ADR to $72.00 and set a buy rating on the stock in a report on Monday, April 22nd. Leerink Swann initiated coverage on shares of GENFIT S A/ADR in a report on Wednesday, April 24th. They set an outperform rating and a $25.47 target price on the stock. Barclays started coverage on shares of GENFIT S A/ADR in a report on Monday, April 22nd. They set an overweight rating and a $55.00 target price on the stock. Finally, Svb Leerink started coverage on shares of GENFIT S A/ADR in a report on Wednesday, April 24th. They issued an outperform rating and a $58.00 price objective on the stock. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. The stock has a consensus rating of Buy and an average target price of $52.62.
Institutional investors and hedge funds have recently made changes to their positions in the company. One68 Global Capital LLC purchased a new position in GENFIT S A/ADR during the 1st quarter worth $270,000. Dean Capital Investments Management LLC purchased a new position in GENFIT S A/ADR during the 1st quarter worth $650,000. TT International purchased a new position in GENFIT S A/ADR during the 1st quarter worth $1,200,000. Finally, Victory Capital Management Inc. purchased a new stake in shares of GENFIT S A/ADR in the first quarter valued at about $2,358,000. Institutional investors and hedge funds own 15.31% of the company’s stock.
GENFIT S A/ADR Company Profile
Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, and autoimmune or fibrotic diseases affecting primarily the liver and gastro-enterology. The company's lead products include Elafibranor, which is in pivotal Phase 3 clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as in Phase 2 study in patients with primary biliary cholangitis; and Nitazoxanide that is in Phase 2 proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis.
Featured Story: What is a short straddle?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for GENFIT S A/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GENFIT S A/ADR and related companies with MarketBeat.com's FREE daily email newsletter.